Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WSC 2026 | Guidance for managing patients who present with cognitive complaints and SVD on MRI

Joanna Wardlaw, CBE, MB ChB (Hons), MD, FRCR, FRCP, FMedSci, FRSE, The University of Edinburgh, Edinburgh, UK, comments on the practical approach for neurologists when patients present with cognitive complaints and small vessel disease (SVD) on MRI, emphasizing the importance of not ignoring SVD and managing vascular risk factors. Prof. Wardlaw highlights the need to assess whether the patient’s cognitive problems might be due to vascular or other pathologies, such as Alzheimer’s, and notes that a more informed approach to dementia treatment may involve a combination of medications targeting different pathologies. This interview took place at the 18th World Stroke Congress (WSC) in Seoul, Korea.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

The first thing is not to ignore it. I think it’s fair to say that memory clinics for a long time have very much focused on the sort of Alzheimer’s end of the spectrum, but actually, a lot of people have some evidence of vascular disease because it’s common. And it’s not uncommon to find vascular disease, small vessel disease on a brain scan. And really, the question then is, is this more than you might expect to see for someone of this age and these other criteria? And we now have actually some quite reasonable information about the range of what you might call within normal limits or not normal limits at different ages, so it’s not just a matter of sort of guessing based on what you see coming through your clinic; you can actually compare your individuals against some normative data...

The first thing is not to ignore it. I think it’s fair to say that memory clinics for a long time have very much focused on the sort of Alzheimer’s end of the spectrum, but actually, a lot of people have some evidence of vascular disease because it’s common. And it’s not uncommon to find vascular disease, small vessel disease on a brain scan. And really, the question then is, is this more than you might expect to see for someone of this age and these other criteria? And we now have actually some quite reasonable information about the range of what you might call within normal limits or not normal limits at different ages, so it’s not just a matter of sort of guessing based on what you see coming through your clinic; you can actually compare your individuals against some normative data. It’s not perfect, but it’s getting better. And really, the thing is that if somebody does have more white matter disease, you know, evidence of vascular disease on their brain scan, you should be looking very carefully, first of all, for what vascular risk factors do they have? Because we know a lot about how to manage vascular risk factors. So, you know, they need good blood pressure management. They need good lipid management. They need good lifestyle advice because actually, a lot of benefit may come from adopting a better diet, getting more exercise. A lot of that’s observational, but it’s also general health advice, so it’s unlikely to do any harm. So, it’s about identifying if there is an obvious vascular risk factor that might be contributing, trying to manage that as effectively as possible, and then after that, you know, how much of this person’s cognitive problem might be vascular – is there any evidence that they might also have some Alzheimer’s pathology? Because these co-pathologies are very common. I suspect in the long run that we will end up in a situation where we’re much more clever about assessing people and what proportion of their clinical condition is vascular or other pathology, and then having a number of different medications that can deal with those different pathologies. Like in stroke prevention, you have anti-platelets and blood pressure lowering and lipid lowering. It’s not just one single thing. So, I would hope that we could move quite rapidly towards a bit more of an informed approach for dementia as well.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJNeurology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.